AU2018301412B2 - Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof - Google Patents

Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof

Info

Publication number
AU2018301412B2
AU2018301412B2 AU2018301412A AU2018301412A AU2018301412B2 AU 2018301412 B2 AU2018301412 B2 AU 2018301412B2 AU 2018301412 A AU2018301412 A AU 2018301412A AU 2018301412 A AU2018301412 A AU 2018301412A AU 2018301412 B2 AU2018301412 B2 AU 2018301412B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
fusion protein
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018301412A
Other languages
English (en)
Other versions
AU2018301412A1 (en
AU2018301412A9 (en
Inventor
Julian Chandler
Nimish GERA
Siddharth JINDAL
Bridget Puffer
Douglas L. Sheridan
Paul P. Tamburini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2018301412A1 publication Critical patent/AU2018301412A1/en
Priority to AU2025200303A priority Critical patent/AU2025200303A1/en
Priority to AU2025200313A priority patent/AU2025200313A1/en
Application granted granted Critical
Publication of AU2018301412B2 publication Critical patent/AU2018301412B2/en
Publication of AU2018301412A9 publication Critical patent/AU2018301412A9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2018301412A 2017-07-11 2018-07-11 Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof Active AU2018301412B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2025200303A AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200313A AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2025200303A Division AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200313A Division AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Publications (3)

Publication Number Publication Date
AU2018301412A1 AU2018301412A1 (en) 2020-01-30
AU2018301412B2 true AU2018301412B2 (en) 2025-08-07
AU2018301412A9 AU2018301412A9 (en) 2025-08-07

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018301412A Active AU2018301412B2 (en) 2017-07-11 2018-07-11 Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
AU2025200313A Pending AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200303A Pending AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2025200313A Pending AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200303A Pending AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Country Status (12)

Country Link
US (3) US11498960B2 (OSRAM)
EP (1) EP3625265A1 (OSRAM)
JP (3) JP7684803B2 (OSRAM)
KR (3) KR20250068795A (OSRAM)
CN (3) CN117327187A (OSRAM)
AU (3) AU2018301412B2 (OSRAM)
BR (1) BR112019028269A2 (OSRAM)
CA (1) CA3067247A1 (OSRAM)
CO (1) CO2020000369A2 (OSRAM)
IL (3) IL271920B2 (OSRAM)
MX (2) MX2024005946A (OSRAM)
WO (1) WO2019014360A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250068795A (ko) 2017-07-11 2025-05-16 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
WO2020092546A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
US20220185853A1 (en) * 2019-04-16 2022-06-16 University Of Washington Amantadine binding protein
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20220122608A (ko) 2019-12-26 2022-09-02 에자이 알앤드디 매니지먼트 가부시키가이샤 보체 c5의 발현을 저해하는 이중 가닥 리보핵산을 함유하는 약제학적 조성물
JP7343618B2 (ja) 2020-01-17 2023-09-12 オリンパス株式会社 発光装置、および駆動装置
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法
CN116472065A (zh) * 2020-10-05 2023-07-21 阿雷克森制药公司 治疗皮肌炎的方法
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015608A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DK1355919T3 (da) * 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
EP1558646A2 (en) * 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
AR056138A1 (es) * 2005-10-21 2007-09-19 Hoffmann La Roche Procedimiento para la expresion recombinante de un polipeptido
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
WO2011112850A2 (en) 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
PL2262831T3 (pl) 2008-03-03 2015-08-31 Novelmed Therapeutics Inc Przeciwciała przeciwko properdynie
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CA2788993A1 (en) * 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP5827994B2 (ja) 2010-07-09 2015-12-02 アフィボディ・アーベー ポリペプチド
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
EP2726103B1 (en) 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
SG11201403416TA (en) 2011-12-21 2014-07-30 Novartis Ag Compositions and methods for antibodies targeting factor p
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
JP6276202B2 (ja) 2012-02-20 2018-02-07 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合するポリペプチド
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
JP7138411B2 (ja) 2013-08-28 2022-09-16 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド
PT3038633T (pt) 2013-08-28 2021-01-14 Ipc Res Llc Polipéptidos estáveis que se ligam ao complemento humano c5
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
KR102613874B1 (ko) * 2017-01-30 2023-12-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
KR20250068795A (ko) 2017-07-11 2025-05-16 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015608A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAARTEN VAN ROY ET AL: "The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis", ARTHRITIS RESEARCH & THERAPY, vol. 17, no. 1, 1 January 2015, pages 1-16 *
ROTHER, R. ET AL., "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", NAT. BIOTECHNOL., vol. 25, 2007, pages 1256 - 64 *

Also Published As

Publication number Publication date
US20250163138A1 (en) 2025-05-22
KR20250099285A (ko) 2025-07-01
KR20200026264A (ko) 2020-03-10
AU2025200313A1 (en) 2025-02-13
WO2019014360A8 (en) 2019-02-21
EP3625265A1 (en) 2020-03-25
CA3067247A1 (en) 2019-01-17
RU2020102910A (ru) 2021-08-11
BR112019028269A2 (pt) 2020-07-14
MX2024005945A (es) 2024-06-11
IL324119A (en) 2025-12-01
IL307197B1 (en) 2025-11-01
JP2020532285A (ja) 2020-11-12
JP2023120208A (ja) 2023-08-29
IL271920A (en) 2020-02-27
JP2025118590A (ja) 2025-08-13
AU2018301412A1 (en) 2020-01-30
IL307197A (en) 2023-11-01
JP7684803B2 (ja) 2025-05-28
US20230235033A1 (en) 2023-07-27
US11498960B2 (en) 2022-11-15
MX2024005946A (es) 2024-06-11
US12221473B2 (en) 2025-02-11
CO2020000369A2 (es) 2020-01-31
CN117327188A (zh) 2024-01-02
AU2025200303A1 (en) 2025-02-13
RU2020102910A3 (OSRAM) 2021-12-02
US20200399351A1 (en) 2020-12-24
KR20250068795A (ko) 2025-05-16
CN111201246A (zh) 2020-05-26
AU2018301412A9 (en) 2025-08-07
IL271920B1 (en) 2023-11-01
WO2019014360A1 (en) 2019-01-17
CN111201246B (zh) 2023-10-27
KR102806328B1 (ko) 2025-05-14
IL271920B2 (en) 2024-03-01
CN117327187A (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
US12221473B2 (en) Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
JP2021036870A (ja) 向上した薬物動態を有する抗ｃ５抗体
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
JP7101684B2 (ja) 一価の抗プロペルジン抗体および抗体断片
JP2020114210A (ja) 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
US20180030141A1 (en) Cx3cr1-binding polypeptides
US20220185875A1 (en) Bispecific antibody specifically bound to vegf and ang2
US20140286957A1 (en) ANTIBODIES TO CD1d
CN113660944A (zh) 用于补体相关疾病的融合蛋白构建体
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
KR20240038716A (ko) 신규 항-masp-2 항체
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2024108529A1 (en) Properdin binding protein and use thereof
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
KR20250112858A (ko) 프로퍼딘 결합 단백질 및 이의 용도
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)